Virtual biopsy for non-invasive identification of follicular lymphoma histologic transformation using radiomics-based imaging biomarker from PET/CT

Table 3 Comparison of the R-signature with the patient clinical data in the t-FL test cohort

Characteristic		R-signature		P value*	SUVmax		P value*
Characteristic		Low (n = 70)	High (n = 35)	P value*	Low (n = 59)	High (n = 46)	P value*
Gender	Male	28	20	0.103	32	25	1.000
Gender	Female	42	15	0.103	27	21	1.000
Age (years)	< 60	60	21	0.006	48	33	0.254
Age (years)	≥ 60	10	14	0.006	11	13	0.254
Elevate LDH	no	65	23	0.001	52	36	0.192
Elevate LDH	yes	5	12	0.001	7	10	0.192
ECOG PS	0–1	59	12	0.026	41	30	0.687
ECOG PS	≥ 2	21	13	0.026	18	16	0.687
Ann arbor staging	I–II	11	9	0.292	13	7	0.457
Ann arbor staging	III–IV	59	26	0.292	46	39	0.457
B symptoms	No	54	29	0.615	47	36	1.000
B symptoms	Yes	16	6	0.615	12	10	1.000
Hemoglobin < 120 g/L	No	45	27	0.265	39	33	0.672
Hemoglobin < 120 g/L	Yes	25	8	0.265	20	13	0.672
Elevate Serum β2-MG	No	38	13	0.147	32	19	0.293
Elevate Serum β2-MG	Yes	32	22	0.147	27	27	0.293

Abbreviations: LDH lactate dehydrogenase, ECOG PS Eastern Cooperative Oncology Group performance status, LDH lactate dehydrogenase, β2-MG β2-microglobulin
^*P value derived from χ² test in t-FL test cohort
A P-value of <0.05 indicates statistical significance

ISSN: 1741-7015